Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.7K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

1.1K
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
1.1K
Seizures: Classification01:13

Seizures: Classification

2.5K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multimodal monitoring in newborn infants with stroke improves prediction of post-neonatal epilepsy.

Developmental medicine and child neurology·2026
Same author

Prolonged fenfluramine use in open-label studies of Dravet or Lennox-Gastaut syndromes: Long-term safety, tolerability, patient global functioning, and considerations for interpreting effectiveness.

Epilepsia·2026
Same author

Electrographic-only seizures and status epilepticus in neonates with Tuberous Sclerosis Complex.

Pediatric research·2026
Same author

Continuing education course on genetic epilepsies was held by the Chilean society of epileptology.

Epileptic disorders : international epilepsy journal with videotape·2026
Same author

Clinically Silent Seizures in Neonates with Tuberous Sclerosis: An International Case Series.

Neonatology·2026
Same author

Efficacy and tolerability of blue-tinted contact lenses in the treatment of Sunflower syndrome: A questionnaire-based study.

Epilepsy & behavior : E&B·2026

Related Experiment Video

Updated: Apr 29, 2026

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.3K

The case for assessing cannabidiol in epilepsy.

Maria Roberta Cilio1, Elizabeth A Thiele, Orrin Devinsky

  • 1Departments of Neurology and Pediatrics, University of California San Francisco, San Francisco, California, U.S.A.

Epilepsia
|May 24, 2014
PubMed
Summary

Cannabidiol (CBD), a nonpsychotropic compound from Cannabis sativa, shows promise for treating intractable epilepsies. Further research is needed to confirm its safety, efficacy, and optimal dosage for treatment-resistant epilepsy.

Keywords:
CannabidiolChildhoodEpilepsy

More Related Videos

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery
10:46

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery

Published on: September 1, 2023

4.1K
Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.3K

Related Experiment Videos

Last Updated: Apr 29, 2026

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.3K
Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery
10:46

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery

Published on: September 1, 2023

4.1K
Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.3K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Medical Chemistry

Background:

  • Intractable epilepsies significantly impair cognitive function, behavior, and quality of life.
  • Cannabidiol (CBD), a nonpsychotropic compound from Cannabis sativa, has demonstrated anticonvulsant properties in preclinical studies.
  • Limited clinical research exists due to issues with compound purity and legal restrictions.

Purpose of the Study:

  • To systematically investigate the safety and pharmacokinetics of pure CBD.
  • To assess potential interactions between CBD and other antiepileptic drugs.
  • To obtain preliminary efficacy data for various CBD dosages in epilepsy treatment.

Main Methods:

  • Systematic investigation of safety and pharmacokinetics.
  • Assessment of drug interactions with existing antiepileptic medications.
  • Exploration of dose-dependent efficacy signals.

Main Results:

  • Basic research indicates CBD possesses anticonvulsant properties and a favorable safety profile.
  • Pure CBD is identified as a potential phytocannabinoid therapy for drug-resistant epilepsy.
  • Data collection is foundational for future placebo-controlled trials.

Conclusions:

  • Pure CBD presents a promising therapeutic candidate for treatment-resistant epilepsy.
  • Further systematic investigation into CBD's safety, pharmacokinetics, and efficacy is warranted.
  • Findings will inform the design of robust clinical trials for epilepsy management.